Table 3. Clinicopathologic variables and the protein expression status of PHLPP1 and PHLPP2.
| Characteristics | No. | PHLPP1 expression n (%) | P value | PHLPP2 expression n (%) | P value | ||
|---|---|---|---|---|---|---|---|
| Low | High | Low | High | ||||
| Gender | 1.000 | 0.640 | |||||
| Male | 126 | 105 (83.3) | 21 (16.7) | 103 (81.7) | 23 (18.3) | ||
| Female | 12 | 10 (83.3) | 2 (16.7) | 11 (91.7) | 1 (8.3) | ||
| Age (years) | 0.819 | 0.653 | |||||
| <60 | 69 | 57 (82.6) | 12 (17.4) | 58 (84.1) | 11 (15.9) | ||
| ≥60 | 69 | 58 (84.1) | 11 (15.9) | 56 (81.2) | 13 (18.8) | ||
| Tobacco | 0.540 | 0.637 | |||||
| Never | 35 | 28 (80.0) | 7 (20.0) | 28 (80.0) | 7 (20.0) | ||
| Ever | 103 | 87 (84.5) | 16 (15.5) | 86 (83.5) | 17 (16.5) | ||
| Alcohol | 1.000 | 0.906 | |||||
| Never | 30 | 25 (83.3) | 5 (16.7) | 25 (83.3) | 5 (16.7) | ||
| Ever | 108 | 90 (83.3) | 18 (16.7) | 89 (82.4) | 19 (17.6) | ||
| Differentiation | 0.001* | 0.006* | |||||
| Well | 26 | 16 (61.5) | 10 (38.5) | 17 (65.4) | 9 (34.6) | ||
| Moderate | 62 | 51 (82.3) | 11 (17.7) | 50 (80.6) | 12 (19.4) | ||
| Poor | 50 | 48 (96.0) | 2 (4.0) | 47 (94.0) | 3 (6.0) | ||
| T stage | 0.047* | 0.081 | |||||
| T1-T2 | 64 | 49 (76.6) | 15 (23.4) | 49 (76.6) | 15 (23.4) | ||
| T3-T4 | 74 | 66 (89.2) | 8 (10.8) | 65 (87.8) | 9 (12.2) | ||
| Clinical stage | 0.001* | 0.035* | |||||
| I-II | 23 | 13 (56.5) | 10 (43.5) | 15 (65.2) | 8 (34.8) | ||
| III-IV | 115 | 102 (88.7) | 13 (11.3) | 99 (86.1) | 16 (13.9) | ||
| LN metastasis | 0.002* | 0.007* | |||||
| N0 | 30 | 18 (60.0) | 12 (40.0) | 21 (70.0) | 9 (30.0) | ||
| N1 | 51 | 46 (90.2) | 5 (9.8) | 40 (78.4) | 11 (21.6) | ||
| N2 | 49 | 45 (91.8) | 4 (8.2) | 47 (95.9) | 2 (4.1) | ||
| N3 | 8 | 6 (75.0) | 2 (25.0) | 6 (75.0) | 2 (25.0) | ||
P values were determined by Pearson Chi-square tests or continuous correction Chi-square tests. LN, lymph node.
*P<0.05